Multisciplinary management of patients with liver metastasis from colorectal cancer

World Journal of Gastroenterology

Volumn 22, Issue 32, 2016, Pages 7215-7225

  De Greef, Kathleen ^a   Rolfo, Christian ^a   Russo, Antonio ^b   Chapelle, Thiery ^a   Bronte, Giuseppe ^b   Passiglia, Francesco ^a,b   Coelho, Andreia ^a,c   Papadimitriou, Konstantinos ^a   Peeters, Marc ^a  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^b UNIVERSITY OF PALERMO   (Italy)

^c Centro Hospitalar de Tras os Montes e Alto Douro   (Portugal)

Author keywords

Chemotherapy; Colorectal cancer; Liver metastases; Liver resection; Multidisciplinary team

Indexed keywords

BEVACIZUMAB; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR;

CANCER CHEMOTHERAPY; CLINICAL EFFECTIVENESS; COLORECTAL CANCER; COLORECTAL LIVER METASTASIS; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG RESPONSE; HUMAN; INTERDISCIPLINARY EDUCATION; LIVER RESECTION; METASTATIC COLORECTAL CANCER; MULTIMODALITY CANCER THERAPY; OUTCOME ASSESSMENT; PATIENT SELECTION; POSTOPERATIVE PERIOD; PRACTICE GUIDELINE; REVIEW; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; COLORECTAL NEOPLASMS; DISEASE MANAGEMENT; LIVER NEOPLASMS; SECONDARY;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; DISEASE MANAGEMENT; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84983552278     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v22.i32.7215     Document Type: Review

References (120)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90 [PMID: 21296855 DOI: 10.3322/caac.20107]
2. Society AC. Cancer facts and figures 2010. Available from: URL: http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2010/
3. Van Cutsem E, Nordlinger B, Adam R, Köhne CH, Pozzo C, Poston G, Ychou M, Rougier P. Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer 2006; 42: 2212-2221 [PMID: 16904315 DOI: 10.1016/j.ejca.2006.04.012]
4. Adam R, Hoti E, Folprecht G, Benson AB. Accomplishments in 2008 in the management of curable metastatic colorectal cancer. Gastrointest Cancer Res 2009; 3: S15-S22 [PMID: 20011559]
5. Weiss L, Grundmann E, Torhorst J, Hartveit F, Moberg I, Eder M, Fenoglio-Preiser CM, Napier J, Horne CH, Lopez MJ. Haematogenous metastatic patterns in colonic carcinoma: an analysis of 1541 necropsies. J Pathol 1986; 150: 195-203 [PMID: 3806280 DOI: 10.1002/path.1711500308]
6. Garden OJ, Rees M, Poston GJ, Mirza D, Saunders M, Ledermann J, Primrose JN, Parks RW. Guidelines for resection of colorectal cancer liver metastases. Gut 2006; 55 Suppl 3: iii1-iii8 [PMID: 16835351 DOI: 10.1136/gut.2006.098053]
7. Chiappa A, Makuuchi M, Lygidakis NJ, Zbar AP, Chong G, Bertani E, Sitzler PJ, Biffi R, Pace U, Bianchi PP, Contino G, Misitano P, Orsi F, Travaini L, Trifirò G, Zampino MG, Fazio N, Goldhirsch A, Andreoni B. The management of colorectal liver metastases: Expanding the role of hepatic resection in the age of multimodal therapy. Crit Rev Oncol Hematol 2009; 72: 65-75 [PMID: 19147371 DOI: 10.1016/j.critrevonc.2008.11.003]
8. Ksienski D, Woods R, Speers C, Kennecke H. Patterns of referral and resection among patients with liver-only metastatic colorectal cancer (MCRC). Ann Surg Oncol 2010; 17: 3085-3093 [PMID: 20839067 DOI: 10.1245/s10434-010-1304-9]
9. Bengtsson G, Carlsson G, Hafström L, Jönsson PE. Natural history of patients with untreated liver metastases from colorectal cancer. Am J Surg 1981; 141: 586-589 [PMID: 7223955 DOI: 10.1016/0002-9610(81)90057-X]
10. Adam R, Bhangui P, Poston G, Mirza D, Nuzzo G, Barroso E, Ijzermans J, Hubert C, Ruers T, Capussotti L, Ouellet JF, Laurent C, Cugat E, Colombo PE, Milicevic M. Is perioperative chemotherapy useful for solitary, metachronous, colorectal liver metastases? Ann Surg 2010; 252: 774-787 [PMID: 21037433 DOI: 10.1097/SLA.0b013e3181fcf3e3]
11. Van den Eynde M, Hendlisz A. Treatment of colorectal liver metastases: a review. Rev Recent Clin Trials 2009; 4: 56-62 [PMID: 19149763 DOI: 10.2174/157488709787047558]
12. Poston GJ, Figueras J, Giuliante F, Nuzzo G, Sobrero AF, Gigot JF, Nordlinger B, Adam R, Gruenberger T, Choti MA, Bilchik AJ, Van Cutsem EJ, Chiang JM, D'Angelica MI. Urgent need for a new staging system in advanced colorectal cancer. J Clin Oncol 2008; 26: 4828-4833 [PMID: 18711170 DOI: 10.1200/JCO.2008.17.6453]
13. Chua TC, Saxena A, Chu F, Zhao J, Morris DL. Predictors of cure after hepatic resection of colorectal liver metastases: an analysis of actual 5- and 10-year survivors. J Surg Oncol 2011; 103: 796-800 [PMID: 21246567 DOI: 10.1002/jso.21864]
14. Taylor A, Kanas G. Survival after surgical resection of hepatic metastases from colorectal cancer: A systematic review and metaanalysis. Ann Oncol 2010; 21 Suppl 8: 632P
15. Scheele J, Stangl R, Schmidt K, Altendorf-Hofmann A. [Recurrent tumor after R0 resection of colorectal liver metastases. Incidence, resectability and prognosis]. Chirurg 1995; 66: 965-973 [PMID: 8529448]
16. Scheele J, Stang R, Altendorf-Hofmann A, Paul M. Resection of colorectal liver metastases. World J Surg 1995; 19: 59-71 [PMID: 7740812 DOI: 10.1007/BF00316981]
17. Figueras J, Valls C, Rafecas A, Fabregat J, Ramos E, Jaurrieta E. Resection rate and effect of postoperative chemotherapy on survival after surgery for colorectal liver metastases. Br J Surg 2001; 88: 980-985 [PMID: 11442531 DOI: 10.1046/j.0007-1323.2001.01821. x]
18. Bismuth H, Adam R, Lévi F, Farabos C, Waechter F, Castaing D, Majno P, Engerran L. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 1996; 224: 509-520; discussion 520-522 [PMID: 8857855]
19. Nordlinger B, Benoist S. Benefits and risks of neoadjuvant therapy for liver metastases. J Clin Oncol 2006; 24: 4954-4955 [PMID: 17075112]
20. Nordlinger B, Guiguet M, Vaillant JC, Balladur P, Boudjema K, Bachellier P, Jaeck D. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Française de Chirurgie. Cancer 1996; 77: 1254-1262 [PMID: 8608500 DOI: 10.1002/(SICI)1097-0142(19960401)77]
21. Fong Y, Salo J. Surgical therapy of hepatic colorectal metastasis. Semin Oncol 1999; 26: 514-523 [PMID: 10528899 DOI: 10.3322/canjclin.49.4.231]
22. Folprecht G, Gruenberger T, Bechstein WO, Raab HR, Lordick F, Hartmann JT, Lang H, Frilling A, Stoehlmacher J, Weitz J, Konopke R, Stroszczynski C, Liersch T, Ockert D, Herrmann T, Goekkurt E, Parisi F, Köhne CH. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 2010; 11: 38-47 [PMID: 19942479 DOI: 10.1016/S1470-2045(09)70330-4]
23. Nordlinger B, Van Cutsem E, Rougier P, Köhne CH, Ychou M, Sobrero A, Adam R, Arvidsson D, Carrato A, Georgoulias V, Giuliante F, Glimelius B, Golling M, Gruenberger T, Tabernero J, Wasan H, Poston G. Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group. Eur J Cancer 2007; 43: 2037-2045 [PMID: 17766104 DOI: 10.1016/j.ejca.2007.07.017]
24. Van Cutsem E, Nordlinger B, Cervantes A. Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment. Ann Oncol 2010; 21 Suppl 5: v93-v97 [PMID: 20555112 DOI: 10.1093/annonc/mdq222]
25. Adam R, Chiche L, Aloia T, Elias D, Salmon R, Rivoire M, Jaeck D, Saric J, Le Treut YP, Belghiti J, Mantion G, Mentha G. Hepatic resection for noncolorectal nonendocrine liver metastases: analysis of 1,452 patients and development of a prognostic model. Ann Surg 2006; 244: 524-535 [PMID: 16998361 DOI: 10.1097/01. sla.0000239036.46827.5f]
26. Adams RB, Haller DG, Roh MS. Improving resectability of hepatic colorectal metastases: expert consensus statement by Abdalla et al. Ann Surg Oncol 2006; 13: 1281-1283 [PMID: 16964448 DOI: 10.1245/s10434-006-9149-y]
27. Isoniemi H, Osterlund P. Surgery combined with oncological treatments in liver metastases from colorectal cancer. Scand J Surg 2011; 100: 35-41 [PMID: 21482503]
28. Schroeder RA, Marroquin CE, Bute BP, Khuri S, Henderson WG, Kuo PC. Predictive indices of morbidity and mortality after liver resection. Ann Surg 2006; 243: 373-379 [PMID: 16495703 DOI: 10.1097/01.sla.0000201483.95911.08]
29. Breitenstein S, Apestegui C, Petrowsky H, Clavien PA. "State of the art" in liver resection and living donor liver transplantation: a worldwide survey of 100 liver centers. World J Surg 2009; 33: 797-803 [PMID: 19172348 DOI: 10.1007/s00268-008-9878-0]
30. Bennink RJ, Dinant S, Erdogan D, Heijnen BH, Straatsburg IH, van Vliet AK, van Gulik TM. Preoperative assessment of postoperative remnant liver function using hepatobiliary scintigraphy. J Nucl Med 2004; 45: 965-971 [PMID: 15181131]
31. Dinant S, de Graaf W, Verwer BJ, Bennink RJ, van Lienden KP, Gouma DJ, van Vliet AK, van Gulik TM. Risk assessment of posthepatectomy liver failure using hepatobiliary scintigraphy and CT volumetry. J Nucl Med 2007; 48: 685-692 [PMID: 17475954 DOI: 10.2967/jnumed.106.038430]
32. Marcos A, Ham JM, Fisher RA, Olzinski AT, Shiffman ML, Sanyal AJ, Luketic VA, Sterling RK, Posner MP. Emergency adult to adult living donor liver transplantation for fulminant hepatic failure. Transplantation 2000; 69: 2202-2205 [PMID: 10852626 DOI: 10.1097/00007890-200005270-00044]
33. Jarnagin WR, Gonen M, Fong Y, DeMatteo RP, Ben-Porat L, Little S, Corvera C, Weber S, Blumgart LH. Improvement in perioperative outcome after hepatic resection: analysis of 1,803 consecutive cases over the past decade. Ann Surg 2002; 236: 397-406; discussion 406-407 [PMID: 12368667]
34. Poon RT, Fan ST, Wong J. Selection criteria for hepatic resection in patients with large hepatocellular carcinoma larger than 10 cm in diameter. J Am Coll Surg 2002; 194: 592-602 [PMID: 12022599 DOI: 10.1016/S1072-7515(02)01163-8]
35. Belghiti J, Hiramatsu K, Benoist S, Massault P, Sauvanet A, Farges O. Seven hundred forty-seven hepatectomies in the 1990s: an update to evaluate the actual risk of liver resection. J Am Coll Surg 2000; 191: 38-46 [PMID: 10898182 DOI: 10.1016/S1072-7515(00)00261-1]
36. Nagino M, Kamiya J, Uesaka K, Sano T, Yamamoto H, Hayakawa N, Kanai M, Nimura Y. Complications of hepatectomy for hilar cholangiocarcinoma. World J Surg 2001; 25: 1277-1283 [PMID: 11596890 DOI: 10.1007/s00268-001-0110-8]
37. Das BC, Isaji S, Kawarada Y. Analysis of 100 consecutive hepatectomies: risk factors in patients with liver cirrhosis or obstructive jaundice. World J Surg 2001; 25: 266-72; discussion 272-3 [PMID: 11343174 DOI: 10.1007/s002680020059]
38. Nagasue N, Yamanoi A, el-Assal ON, Ohmori H, Tachibana M, Kimoto T, Kohno H. Major compared with limited hepatic resection for hepatocellular carcinoma without underlying cirrhosis: a retrospective analysis. Eur J Surg 1999; 165: 638-646 [PMID: 10452257 DOI: 10.1080/11024159950189681]
39. Nagasue N. Liver resection for hepatocellular carcinoma: indications, techniques, complications, and prognostic factors. J Hepatobiliary Pancreat Surg 1998; 5: 7-13 [PMID: 9683747 DOI: 10.1007/PL00009954]
40. Tsao JI, DeSanctis J, Rossi RL, Oberfield RA. Hepatic malignancies. Surg Clin North Am 2000; 80: 603-632 [PMID: 10836009 DOI: 10.1016/S0039-6109(05)70203-6]
41. Tsao JI, Loftus JP, Nagorney DM, Adson MA, Ilstrup DM. Trends in morbidity and mortality of hepatic resection for malignancy. A matched comparative analysis. Ann Surg 1994; 220: 199-205 [PMID: 8053742 DOI: 10.1097/00000658-199408000-00012]
42. Nonami T, Nakao A, Kurokawa T, Inagaki H, Matsushita Y, Sakamoto J, Takagi H. Blood loss and ICG clearance as best prognostic markers of post-hepatectomy liver failure. Hepatogastroenterology 1999; 46: 1669-1672 [PMID: 10430318]
43. Fortner JG, Fong Y. Twenty-five-year follow-up for liver resection: the personal series of Dr. Joseph G. Fortner. Ann Surg 2009; 250: 908-913 [PMID: 19855260 DOI: 10.1097/SLA.0b013e3181b59491]
44. Nordlinger B, Benoist S. [Recent advances in the case management of colorectal cancer liver metastases]. Bull Acad Natl Med 2003; 187: 899-904 [PMID: 14979055]
45. Schneider PD. Preoperative assessment of liver function. Surg Clin North Am 2004; 84: 355-373 [PMID: 15062650 DOI: 10.1016/S0039-6109(03)00224-X]
46. Zorzi D, Laurent A, Pawlik TM, Lauwers GY, Vauthey JN, Abdalla EK. Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases. Br J Surg 2007; 94: 274-286 [PMID: 17315288 DOI: 10.1002/bjs.5719]
47. Peppercorn PD, Reznek RH, Wilson P, Slevin ML, Gupta RK. Demonstration of hepatic steatosis by computerized tomography in patients receiving 5-fluorouracil-based therapy for advanced colorectal cancer. Br J Cancer 1998; 77: 2008-2011 [PMID: 9667683 DOI: 10.1038/bjc.1998.333]
48. Kooby DA, Stockman J, Ben-Porat L, Gonen M, Jarnagin WR, Dematteo RP, Tuorto S, Wuest D, Blumgart LH, Fong Y. Influence of transfusions on perioperative and long-term outcome in patients following hepatic resection for colorectal metastases. Ann Surg 2003; 237: 860-869; discussion 869-870 [PMID: 12796583 DOI: 10.1097/01.SLA.0000072371.95588.DA]
49. Vauthey JN, Pawlik TM, Ribero D, Wu TT, Zorzi D, Hoff PM, Xiong HQ, Eng C, Lauwers GY, Mino-Kenudson M, Risio M, Muratore A, Capussotti L, Curley SA, Abdalla EK. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006; 24: 2065-2072 [PMID: 16648507 DOI: 10.1200/JCO.2005.05.3074]
50. Fernandez FG, Ritter J, Goodwin JW, Linehan DC, Hawkins WG, Strasberg SM. Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg 2005; 200: 845-853 [PMID: 15922194 DOI: 10.1016/j.jamcollsurg.2005.01.024]
51. Dinant S, Gerhards MF, Rauws EA, Busch OR, Gouma DJ, van Gulik TM. Improved outcome of resection of hilar cholangiocarcinoma (Klatskin tumor). Ann Surg Oncol 2006; 13: 872-880 [PMID: 16614876 DOI: 10.1245/ASO.2006.05.053]
52. Erdogan D, Heijnen BH, Bennink RJ, Kok M, Dinant S, Straatsburg IH, Gouma DJ, van Gulik TM. Preoperative assessment of liver function: a comparison of 99mTc-Mebrofenin scintigraphy with indocyanine green clearance test. Liver Int 2004; 24: 117-123 [PMID: 15078475 DOI: 10.1111/j.1478-3231.2004.00901.x]
53. Lalmahomed ZS, Ayez N, van der Pool AE, Verheij J, Ijzermans JN, Verhoef C. Anatomical versus nonanatomical resection of colorectal liver metastases: is there a difference in surgical and oncological outcome? World J Surg 2011; 35: 656-661 [PMID: 21161655 DOI: 10.1007/s00268-010-0890-9]
54. DeMatteo RP, Palese C, Jarnagin WR, Sun RL, Blumgart LH, Fong Y. Anatomic segmental hepatic resection is superior to wedge resection as an oncologic operation for colorectal liver metastases. J Gastrointest Surg 2000; 4: 178-184 [PMID: 10675241 DOI: 10.1016/S1091-255X(00)80054-2]
55. Hasegawa K, Kokudo N, Imamura H, Matsuyama Y, Aoki T, Minagawa M, Sano K, Sugawara Y, Takayama T, Makuuchi M. Prognostic impact of anatomic resection for hepatocellular carcinoma. Ann Surg 2005; 242: 252-259 [PMID: 16041216 DOI: 10.1097/01.sla.0000171307.37401.db]
56. Wakai T, Shirai Y, Sakata J, Kaneko K, Cruz PV, Akazawa K, Hatakeyama K. Anatomic resection independently improves longterm survival in patients with T1-T2 hepatocellular carcinoma. Ann Surg Oncol 2007; 14: 1356-1365 [PMID: 17252289 DOI: 10.1245/s10434-006-9318-z]
57. Ueno S, Kubo F, Sakoda M, Hiwatashi K, Tateno T, Mataki Y, Maemura K, Shinchi H, Natsugoe S, Aikou T. Efficacy of anatomic resection vs nonanatomic resection for small nodular hepatocellular carcinoma based on gross classification. J Hepatobiliary Pancreat Surg 2008; 15: 493-500 [PMID: 18836803 DOI: 10.1007/s00534-007-1312-8]
58. Yokoi Y, Suzuki S, Nakamura S. [The impact of hepatic resection on metastatic colorectal cancer]. Gan To Kagaku Ryoho 2002; 29: 848-855 [PMID: 12090034]
59. Suzuki S, Sakaguchi T, Yokoi Y, Kurachi K, Okamoto K, Okumura T, Tsuchiya Y, Nakamura T, Konno H, Baba S, Nakamura S. Impact of repeat hepatectomy on recurrent colorectal liver metastases. Surgery 2001; 129: 421-428 [PMID: 11283532 DOI: 10.1016/S0039-6060(01)83158-5]
60. Zorzi D, Mullen JT, Abdalla EK, Pawlik TM, Andres A, Muratore A, Curley SA, Mentha G, Capussotti L, Vauthey JN. Comparison between hepatic wedge resection and anatomic resection for colorectal liver metastases. J Gastrointest Surg 2006; 10: 86-94 [PMID: 16368496 DOI: 10.1016/j.gassur.2005.07.022]
61. Gold JS, Are C, Kornprat P, Jarnagin WR, Gönen M, Fong Y, DeMatteo RP, Blumgart LH, D'Angelica M. Increased use of parenchymal-sparing surgery for bilateral liver metastases from colorectal cancer is associated with improved mortality without change in oncologic outcome: trends in treatment over time in 440 patients. Ann Surg 2008; 247: 109-117 [PMID: 18156930 DOI: 10.1097/SLA.0b013e3181557e47]
62. Stewart GD, O'Súilleabháin CB, Madhavan KK, Wigmore SJ, Parks RW, Garden OJ. The extent of resection influences outcome following hepatectomy for colorectal liver metastases. Eur J Surg Oncol 2004; 30: 370-376 [PMID: 15063889 DOI: 10.1016/j.ejso.2004.01.011]
63. Karanjia ND, Lordan JT, Quiney N, Fawcett WJ, Worthington TR, Remington J. A comparison of right and extended right hepatectomy with all other hepatic resections for colorectal liver metastases: a ten-year study. Eur J Surg Oncol 2009; 35: 65-70 [PMID: 18222623 DOI: 10.1016/j.ejso.2007.12.002]
64. Harun N, Nikfarjam M, Muralidharan V, Christophi C. Liver regeneration stimulates tumor metastases. J Surg Res 2007; 138: 284-290 [PMID: 17254608 DOI: 10.1016/j.jss.2006.06.024]
65. Jiang WG, Hiscox S. Hepatocyte growth factor/scatter factor, a cytokine playing multiple and converse roles. Histol Histopathol 1997; 12: 537-555 [PMID: 9151142]
66. Castillo MH, Doerr RJ, Paolini N, Cohen S, Goldrosen M. Hepatectomy prolongs survival of mice with induced liver metastases. Arch Surg 1989; 124: 167-169 [PMID: 2916937 DOI: 10.1001/archsurg.1989.01410020037005]
67. Doerr R, Castillo M, Evans P, Paolini N, Goldrosen M, Cohen SA. Partial hepatectomy augments the liver's antitumor response. Arch Surg 1989; 124: 170-174 [PMID: 2464982 DOI: 10.1001/archsurg.1989.01410020040006]
68. Fausto N, Campbell JS, Riehle KJ. Liver regeneration. Hepatology 2006; 43: S45-S53 [PMID: 16447274 DOI: 10.1002/hep.20969]
69. Fausto N. Growth factors in liver development, regeneration and carcinogenesis. Prog Growth Factor Res 1991; 3: 219-234 [PMID: 1667366 DOI: 10.1016/0955-2235(91)90008-R]
70. Fausto N, Webber EM. Mechanisms of growth regulation in liver regeneration and hepatic carcinogenesis. Prog Liver Dis 1993; 11: 115-137 [PMID: 8272507]
71. Mangnall D, Smith K, Bird NC, Majeed AW. Early increases in plasminogen activator activity following partial hepatectomy in humans. Comp Hepatol 2004; 3: 11 [PMID: 15617575 DOI: 10.1186/1476-5926-3-11]
72. Ikeda Y, Matsumata T, Takenaka K, Sasaki O, Soejima K, Sugimachi K. Preliminary report of tumor metastasis during liver regeneration after hepatic resection in rats. Eur J Surg Oncol 1995; 21: 188-190 [PMID: 7720894 DOI: 10.1016/S0748-7983(95)90468-9]
73. Mizutani J, Hiraoka T, Yamashita R, Miyauchi Y. Promotion of hepatic metastases by liver resection in the rat. Br J Cancer 1992; 65: 794-797 [PMID: 1616850 DOI: 10.1038/bjc.1992.170]
74. Vauthey JN. Colorectal liver metastases: treat effectively up front and consider the borderline resectable. J Clin Oncol 2007; 25: 4524-4525 [PMID: 17925547 DOI: 10.1200/JCO.2007.13.1136]
75. Giacchetti S, Itzhaki M, Gruia G, Adam R, Zidani R, Kunstlinger F, Brienza S, Alafaci E, Bertheault-Cvitkovic F, Jasmin C, Reynes M, Bismuth H, Misset JL, Lévi F. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 1999; 10: 663-669 [PMID: 10442188 DOI: 10.1023/A: 1008347829017]
76. Falcone A, Ricci S, Brunetti I, Pfanner E, Allegrini G, Barbara C, Crinò L, Benedetti G, Evangelista W, Fanchini L, Cortesi E, Picone V, Vitello S, Chiara S, Granetto C, Porcile G, Fioretto L, Orlandini C, Andreuccetti M, Masi G. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 2007; 25: 1670-1676 [PMID: 17470860 DOI: 10.1200/JCO.2006.09.0928]
77. Ychou M, Rivoire M, Thezenas S, Quenet F, Delpero JR, Rebischung C, Letoublon C, Guimbaud R, Francois E, Ducreux M, Desseigne F, Fabre JM, Assenat E. A randomized phase II trial of three intensified chemotherapy regimens in first-line treatment of colorectal cancer patients with initially unresectable or not optimally resectable liver metastases. The METHEP trial. Ann Surg Oncol 2013; 20: 4289-4297 [PMID: 23955585 DOI: 10.1245/s10434-013-3217-x]
78. Nathan H, de Jong MC, Pulitano C, Ribero D, Strub J, Mentha G, Gigot JF, Schulick RD, Choti MA, Aldrighetti L, Capussotti L, Pawlik TM. Conditional survival after surgical resection of colorectal liver metastasis: an international multi-institutional analysis of 949 patients. J Am Coll Surg 2010; 210: 755-764, 764-766 [PMID: 20421045]
79. House MG, Ito H, Gönen M, Fong Y, Allen PJ, DeMatteo RP, Brennan MF, Blumgart LH, Jarnagin WR, D'Angelica MI. Survival after hepatic resection for metastatic colorectal cancer: trends in outcomes for 1,600 patients during two decades at a single institution. J Am Coll Surg 2010; 210: 744-752, 752-755 [PMID: 20421043]
80. Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole ET, Finch-Jones M, Jaeck D, Mirza D, Parks RW, Mauer M, Tanis E, Van Cutsem E, Scheithauer W, Gruenberger T. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): longterm results of a randomised, controlled, phase 3 trial. Lancet Oncol 2013; 14: 1208-1215 [PMID: 24120480 DOI: 10.1016/S1470-2045(13)70447-9]
81. Peeters M, Price T. Biologic therapies in the metastatic colorectal cancer treatment continuum-applying current evidence to clinical practice. Cancer Treat Rev 2012; 38: 397-406 [PMID: 21899955 DOI: 10.1016/j.ctrv.2011.08.002]
82. Kabbinavar FF, Schulz J, McCleod M, Patel T, Hamm JT, Hecht JR, Mass R, Perrou B, Nelson B, Novotny WF. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 2005; 23: 3697-3705 [PMID: 15738537 DOI: 10.1200/JCO.2005.05.112]
83. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342 [PMID: 15175435 DOI: 10.1056/NEJMoa032691]
84. Giantonio BJ, Levy DE, O'dwyer PJ, Meropol NJ, Catalano PJ, Benson AB. A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the Eastern Cooperative Oncology Group study E2200. Ann Oncol 2006; 17: 1399-1403 [PMID: 16873427 DOI: 10.1093/annonc/mdl161]
85. Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzén F, Cassidy J. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26: 2013-2019 [PMID: 18421054 DOI: 10.1200/JCO.2007.14.9930]
86. Gordon CR, Rojavin Y, Patel M, Zins JE, Grana G, Kann B, Simons R, Atabek U. A review on bevacizumab and surgical wound healing: an important warning to all surgeons. Ann Plast Surg 2009; 62: 707-709 [PMID: 19461291 DOI: 10.1097/SAP.0b013e3181828141]
87. Tamiya A, Yamazaki K, Boku N, Machida N, Kojima T, Taku K, Yasui H, Fukutomi A, Hironaka S, Onozawa Y. Safety of bevacizumab treatment in combination with standard chemotherapy for metastatic colorectal cancer: a retrospective review of 65 Japanese patients. Int J Clin Oncol 2009; 14: 513-517 [PMID: 19967487 DOI: 10.1007/s10147-009-0911-6]
88. Van Cutsem E, Rivera F, Berry S, Kretzschmar A, Michael M, DiBartolomeo M, Mazier MA, Canon JL, Georgoulias V, Peeters M, Bridgewater J, Cunningham D. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol 2009; 20: 1842-1847 [PMID: 19406901 DOI: 10.1093/annonc/mdp233]
89. Okines A, Puerto OD, Cunningham D, Chau I, Van Cutsem E, Saltz L, Cassidy J. Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial. Br J Cancer 2009; 101: 1033-1038 [PMID: 19789532 DOI: 10.1038/sj.bjc.6605259]
90. Wong R, Cunningham D, Barbachano Y, Saffery C, Valle J, Hickish T, Mudan S, Brown G, Khan A, Wotherspoon A, Strimpakos AS, Thomas J, Compton S, Chua YJ, Chau I. A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liveronly metastases not selected for upfront resection. Ann Oncol 2011; 22: 2042-2048 [PMID: 21285134 DOI: 10.1093/annonc/mdq714]
91. Loupakis F, Cremolini C. FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus bev as first line treatment of metastatic colorectal cancer (mCRC): Results of the phase III randomized TRIBE trial. J Clin Oncol 2013; 30: 2012
92. Martin RC, Scoggins CR, Schreeder M, Rilling WS, Laing CJ, Tatum CM, Kelly LR, Garcia-Monaco RD, Sharma VR, Crocenzi TS, Strasberg SM. Randomized controlled trial of irinotecan drugeluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis. Cancer 2015; 121: 3649-3658 [PMID: 26149602 DOI: 10.1002/cncr.29534]
93. Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocákova I, Ruff P, Błasińska-Morawiec M, Šmakal M, Canon JL, Rother M, Williams R, Rong A, Wiezorek J, Sidhu R, Patterson SD. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013; 369: 1023-1034 [PMID: 24024839 DOI: 10.1056/NEJMoa1305275]
94. Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, Donea S, Ludwig H, Schuch G, Stroh C, Loos AH, Zubel A, Koralewski P. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009; 27: 663-671 [PMID: 19114683 DOI: 10.1200/JCO.2008.20.8397]
95. Van Cutsem E, Köhne CH, Láng I, Folprecht G, Nowacki MP, Cascinu S, Shchepotin I, Maurel J, Cunningham D, Tejpar S, Schlichting M, Zubel A, Celik I, Rougier P, Ciardiello F. Cetuximab plus irinotecan, fluorouracil, and leucovorin as firstline treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011; 29: 2011-2019 [PMID: 21502544 DOI: 10.1200/JCO.2010.33.5091]
96. Garufi C, Torsello A, Tumolo S, Ettorre GM, Zeuli M, Campanella C, Vennarecci G, Mottolese M, Sperduti I, Cognetti F. Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial. Br J Cancer 2010; 103: 1542-1547 [PMID: 20959822 DOI: 10.1038/sj.bjc.6605940]
97. Ye LC, Liu TS, Ren L, Wei Y, Zhu DX, Zai SY, Ye QH, Yu Y, Xu B, Qin XY, Xu J. Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases. J Clin Oncol 2013; 31: 1931-1938 [PMID: 23569301 DOI: 10.1200/JCO.2012.44.8308]
98. Maughan TS, Adams RA, Smith CG, Meade AM, Seymour MT, Wilson RH, Idziaszczyk S, Harris R, Fisher D, Kenny SL, Kay E, Mitchell JK, Madi A, Jasani B, James MD, Bridgewater J, Kennedy MJ, Claes B, Lambrechts D, Kaplan R, Cheadle JP. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 2011; 377: 2103-2114 [PMID: 21641636 DOI: 10.1016/S0140-6736(11)60613-2]
99. Tveit KM, Guren T, Glimelius B, Pfeiffer P, Sorbye H, Pyrhonen S, Sigurdsson F, Kure E, Ikdahl T, Skovlund E, Fokstuen T, Hansen F, Hofsli E, Birkemeyer E, Johnsson A, Starkhammar H, Yilmaz MK, Keldsen N, Erdal AB, Dajani O, Dahl O, Christoffersen T. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDICVII study. J Clin Oncol 2012; 30: 1755-1762 [PMID: 22473155 DOI: 10.1200/JCO.2011.38.0915]
100. Köhne CH, Hofheinz R, Mineur L, Letocha H, Greil R, Thaler J, Fernebro E, Gamelin E, Decosta L, Karthaus M. First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer. J Cancer Res Clin Oncol 2012; 138: 65-72 [PMID: 21960318 DOI: 10.1007/s00432-011-1061-6]
101. Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocákova I, Ruff P, Błasińska-Morawiec M, Šmakal M, Canon JL, Rother M, Oliner KS, Wolf M, Gansert J. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010; 28: 4697-4705 [PMID: 20921465 DOI: 10.1200/JCO.2009.27.4860]
102. Peeters M, Tabernero J. Resection Rates and Survival in Patients with Wild-Type KRAS/NRAS Metastatic Colorectal Cancer and Liver Metastases: Data from the PRIME Study. Markers in cancer - ASCO, EORTC and NCI meeting, 2013
103. Vauthey JN, Choti MA, Helton WS. AHPBA/SSO/SSAT Consensus Conference on hepatic colorectal metastases: rationale and overview of the conference. January 25, 2006. Ann Surg Oncol 2006; 13: 1259-1260 [PMID: 16952025 DOI: 10.1245/s10434-006-9017-9]
104. Stangl R, Altendorf-Hofmann A, Charnley RM, Scheele J. Factors influencing the natural history of colorectal liver metastases. Lancet 1994; 343: 1405-1410 [PMID: 7515134 DOI: 10.1016/S0140-6736(94)92529-1]
105. Rees M, Plant G, Bygrave S. Late results justify resection for multiple hepatic metastases from colorectal cancer. Br J Surg 1997; 84: 1136-1140 [PMID: 9278662 DOI: 10.1002/bjs.1800840828]
106. Vauthey JN, Nordlinger B, Kopetz S, Poston G. Sequenced chemotherapy and surgery for potentially resectable colorectal liver metastases: a debate over goals of research and an approach while the jury remains out. Ann Surg Oncol 2010; 17: 1983-1986 [PMID: 20232164 DOI: 10.1245/s10434-010-1007-2]
107. Nordlinger B, Vaillant JC, Guiguet M, Balladur P, Paris F, Bachellier P, Jaeck D. Survival benefit of repeat liver resections for recurrent colorectal metastases: 143 cases. Association Francaise de Chirurgie. J Clin Oncol 1994; 12: 1491-1496 [PMID: 8021741]
108. Ruiz-Tovar J, López Hervás P. Repeated liver resection for recurrence of colorectal cancer metastases. Clin Transl Oncol 2010; 12: 634-638 [PMID: 20851805 DOI: 10.1007/s12094-010-0569-6]
109. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999; 230: 309-318; discussion 318-321 [PMID: 10493478 DOI: 10.1097/00000658-199909000-00004]
110. Mann CD, Metcalfe MS, Leopardi LN, Maddern GJ. The clinical risk score: emerging as a reliable preoperative prognostic index in hepatectomy for colorectal metastases. Arch Surg 2004; 139: 1168-1172 [PMID: 15545561 DOI: 10.1001/archsurg.139.11.1168]
111. Nagashima I, Takada T, Nagawa H, Muto T, Okinaga K. Proposal of a new and simple staging system of colorectal liver metastasis. World J Gastroenterol 2006; 12: 6961-6965 [PMID: 17109517 DOI: 10.3748/wjg.v12.i43.6961]
112. Nagashima I, Takada T, Adachi M, Nagawa H, Muto T, Okinaga K. Proposal of criteria to select candidates with colorectal liver metastases for hepatic resection: comparison of our scoring system to the positive number of risk factors. World J Gastroenterol 2006; 12: 6305-6309 [PMID: 17072953 DOI: 10.3748/wjg.v12.i39.6305]
113. Chun YS, Laurent A, Maru D, Vauthey JN. Management of chemotherapy-associated hepatotoxicity in colorectal liver metastases. Lancet Oncol 2009; 10: 278-286 [PMID: 19261256 DOI: 10.1016/S1470-2045(09)70064-6]
114. Karagkounis G, Torbenson MS, Daniel HD, Azad NS, Diaz LA, Donehower RC, Hirose K, Ahuja N, Pawlik TM, Choti MA. Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastases. Cancer 2013; 119: 4137-4144 [PMID: 24104864 DOI: 10.1002/cncr.28347]
115. Nash GM, Gimbel M, Shia J, Nathanson DR, Ndubuisi MI, Zeng ZS, Kemeny N, Paty PB. KRAS mutation correlates with accelerated metastatic progression in patients with colorectal liver metastases. Ann Surg Oncol 2010; 17: 572-578 [PMID: 19727962 DOI: 10.1245/s10434-009-0605-3]
116. Stremitzer S, Stift J, Gruenberger B, Tamandl D, Aschacher T, Wolf B, Wrba F, Gruenberger T. KRAS status and outcome of liver resection after neoadjuvant chemotherapy including bevacizumab. Br J Surg 2012; 99: 1575-1582 [PMID: 23027075 DOI: 10.1002/bjs.8909]
117. Vauthey JN, Zimmitti G, Kopetz SE, Shindoh J, Chen SS, Andreou A, Curley SA, Aloia TA, Maru DM. RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. Ann Surg 2013; 258: 619-626; discussion 626-627 [PMID: 24018645]
118. Lordan JT, Karanjia ND, Quiney N, Fawcett WJ, Worthington TR. A 10-year study of outcome following hepatic resection for colorectal liver metastases - The effect of evaluation in a multidisciplinary team setting. Eur J Surg Oncol 2009; 35: 302-306 [PMID: 18328668 DOI: 10.1016/j.ejso.2008.01.028]
119. Adam R, Haller DG, Poston G, Raoul JL, Spano JP, Tabernero J, Van Cutsem E. Toward optimized front-line therapeutic strategies in patients with metastatic colorectal cancer-an expert review from the International Congress on Anti-Cancer Treatment (ICACT) 2009. Ann Oncol 2010; 21: 1579-1584 [PMID: 20219759 DOI: 10.1093/annonc/mdq043]
120. Ruiz-Tovar J, López Hervás P. Value of third metastasectomy of colorectal adenocarcinoma. Clin Transl Oncol 2007; 9: 56-58 [PMID: 17272232 DOI: 10.1007/s12094-007-0011-x]